Cisplatin Rapidly Down-regulates Its Own Influx Transporter hCTR1 in Cultured Human Ovarian Carcinoma Cells

Purpose: Cisplatin (DDP)-resistant cells commonly exhibit reduced drug accumulation. Previous studies have shown that the major copper (Cu) influx transporter CTR1 controls the uptake of DDP in yeast and mammalian cells. The goal of this study was to examine the effect of Cu and DDP on the level and subcellular localization of hCTR1 protein in human ovarian carcinoma cells. Experimental Design: Cultured human ovarian carcinoma A2780 cells were exposed to DDP and Cu, and the effect on hCTR1 was determined using Western blot analysis and confocal digital deconvolution microscopy. Results: Loss of hCTR1 was triggered by DDP exposure in a concentration and time-dependent manner. Exposure to 0.5 μmol/L DDP for 5 minutes reduced hCTR1 levels and exposure to DDP concentrations ≥2 μmol/L caused almost complete disappearance. The loss of hCTR1 was observed within 1 minute of the start of exposure to 2 μmol/L DDP. Treatment of cells with 100 μmol/L Cu for 5 minutes produced a smaller effect. Pretreatment of cells with 2 μmol/L DDP for 5 minutes resulted in a 50% decrease in 64Cu uptake, demonstrating that the DDP-induced loss of hCTR1 detected by Western blot analysis and imaging was functionally significant. Conclusions: DDP down-regulated the amount of its major influx transporter in cultured human ovarian carcinoma cells in a concentration- and time-dependent manner. The effect was observed at DDP concentrations within the range found in the plasma of patients being treated with DDP, and it occurred very quickly relative to the half-life of the drug.

[1]  D. Thiele,et al.  Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Cebrián,et al.  Studies on the mechanisms of arsenic-induced self tolerance developed in liver epithelial cells through continuous low-level arsenite exposure. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  D. Thiele,et al.  Characterization of Mouse Embryonic Cells Deficient in the Ctr1 High Affinity Copper Transporter , 2002, The Journal of Biological Chemistry.

[4]  D. Thiele,et al.  Biochemical and Genetic Analyses of Yeast and Human High Affinity Copper Transporters Suggest a Conserved Mechanism for Copper Uptake* , 2002, The Journal of Biological Chemistry.

[5]  D. Thiele,et al.  Biochemical Characterization of the Human Copper Transporter Ctr1* , 2002, The Journal of Biological Chemistry.

[6]  D. Thiele,et al.  A delicate balance: homeostatic control of copper uptake and distribution. , 1999, The Journal of nutrition.

[7]  A. Naganuma,et al.  Effect of copper pretreatment on toxicity and antitumor activity of cis-diamminedichloroplatinum in mice. , 1984, Research communications in chemical pathology and pharmacology.

[8]  A. Pa,et al.  Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. , 1990 .

[9]  D. Thiele,et al.  Isolation of a murine copper transporter gene, tissue specific expression and functional complementation of a yeast copper transport mutant. , 2000, Gene.

[10]  G. Samimi,et al.  Cross-resistance to cisplatin in cells with acquired resistance to copper , 2004, Cancer Chemotherapy and Pharmacology.

[11]  J. Bonifacino,et al.  Copper‐dependent degradation of the Saccharomyces cerevisiae plasma membrane copper transporter Ctr1p in the apparent absence of endocytosis. , 1996, The EMBO journal.

[12]  M. Winker,et al.  Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. , 1985, Biochemical pharmacology.

[13]  I. Herskowitz,et al.  Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[15]  D. Thiele,et al.  Copper-stimulated Endocytosis and Degradation of the Human Copper Transporter, hCtr1* , 2003, The Journal of Biological Chemistry.

[16]  S. Howell,et al.  Cellular accumulation of the anticancer agent cisplatin: a review. , 1993, British Journal of Cancer.

[17]  Bing Zhou,et al.  hCTR1: a human gene for copper uptake identified by complementation in yeast. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Kaplan,et al.  Molecular Characterization of hCTR1, the Human Copper Uptake Protein* , 2002, The Journal of Biological Chemistry.

[19]  L. Møller,et al.  Characterization of the hCTR1 gene: genomic organization, functional expression, and identification of a highly homologous processed gene. , 2000, Gene.

[20]  B. Tops,et al.  Biochemical characterization and subcellular localization of human copper transporter 1 (hCTR1). , 2002, The Biochemical journal.

[21]  Dominique L. Cosco,et al.  The copper transporter CTR1 provides an essential function in mammalian embryonic development , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  S. Howell,et al.  Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. , 1990, Cancer cells.

[23]  Myriam Rochdi,et al.  Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. , 2002, Cancer research.

[24]  E. D. Harris,et al.  Copper transport and kinetics in cultured C6 rat glioma cells. , 1995, The American journal of physiology.

[25]  P. Disaia,et al.  Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors. , 1972, American journal of obstetrics and gynecology.

[26]  S. Howell,et al.  The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. , 2002, Molecular pharmacology.

[27]  R. Tobey,et al.  Differential response of cultured human normal and tumor cells to trace element-induced resistance to the alkylating agent melphalan. , 1985, Cancer research.